159 related articles for article (PubMed ID: 28738014)
21. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential.
Sun R; Shen J; Gao Y; Zhou Y; Yu Z; Hornicek F; Kan Q; Duan Z
Oncotarget; 2016 Jun; 7(25):38333-38346. PubMed ID: 27223261
[TBL] [Abstract][Full Text] [Related]
23. Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.
Cho YJ; Kim SH; Kim EK; Han JW; Shin KH; Hu H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Jung ST; Kim HS
BMC Cancer; 2018 Feb; 18(1):158. PubMed ID: 29415665
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.
Zhou Y; Chen D; Qi Y; Liu R; Li S; Zou H; Lan J; Ju X; Jiang J; Liang W; Shen Y; Pang L; Li F
Oncol Rep; 2017 Jun; 37(6):3351-3360. PubMed ID: 28498445
[TBL] [Abstract][Full Text] [Related]
26. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
27. MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2.
Huo Y; Li Q; Wang X; Jiao X; Zheng J; Li Z; Pan X
Oncotarget; 2017 Jul; 8(29):46993-47006. PubMed ID: 28388584
[TBL] [Abstract][Full Text] [Related]
28. EZH2 overexpression is associated with poor prognosis in patients with glioma.
Zhang Y; Yu X; Chen L; Zhang Z; Feng S
Oncotarget; 2017 Jan; 8(1):565-573. PubMed ID: 27880940
[TBL] [Abstract][Full Text] [Related]
29. Enhancer of zeste homolog 2 (EZH2) regulates tumor angiogenesis and predicts recurrence and prognosis of intrahepatic cholangiocarcinoma.
Nakagawa S; Okabe H; Ouchi M; Tokunaga R; Umezaki N; Higashi T; Kaida T; Arima K; Kitano Y; Kuroki H; Mima K; Nitta H; Imai K; Hashimoto D; Yamashita YI; Chikamoto A; Baba H
HPB (Oxford); 2018 Oct; 20(10):939-948. PubMed ID: 29759640
[TBL] [Abstract][Full Text] [Related]
30. Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions.
Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Yamanaka A; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
BMC Cancer; 2017 Feb; 17(1):160. PubMed ID: 28241804
[TBL] [Abstract][Full Text] [Related]
31. Aberrant expression of enhancer of zeste homologue 2, correlated with HIF-1α, refines relapse risk and predicts poor outcome for breast cancer.
Dong M; Fan XJ; Chen ZH; Wang TT; Li X; Chen J; Lin Q; Wen JY; Ma XK; Wei L; Ruan DY; Lin ZX; Liu Q; Wu XY; Wan XB
Oncol Rep; 2014 Sep; 32(3):1101-7. PubMed ID: 25017254
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of EZH2 expression in patients with oesophageal cancer: a meta-analysis.
Wang Y; Gao F; Zhao M; Li B; Xing D; Wang J; Yang Y
J Cell Mol Med; 2016 May; 20(5):836-41. PubMed ID: 26859127
[TBL] [Abstract][Full Text] [Related]
33. Correlation between EZH2 and CEP55 and lung adenocarcinoma prognosis.
Wu S; Wu D; Pan Y; Liu H; Shao Z; Wang M
Pathol Res Pract; 2019 Feb; 215(2):292-301. PubMed ID: 30527357
[TBL] [Abstract][Full Text] [Related]
34. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas.
Lagarde P; Przybyl J; Brulard C; Pérot G; Pierron G; Delattre O; Sciot R; Wozniak A; Schöffski P; Terrier P; Neuville A; Coindre JM; Italiano A; Orbach D; Debiec-Rychter M; Chibon F
J Clin Oncol; 2013 Feb; 31(5):608-15. PubMed ID: 23319690
[TBL] [Abstract][Full Text] [Related]
35. High expression of enhancer of zeste homologue 2 indicates poor prognosis in patients with soft tissue sarcomas.
Yamaga K; Osaki M; Kidani K; Shomori K; Yoshida H; Ito H
Mol Med Rep; 2008; 1(5):633-9. PubMed ID: 21479461
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of Enhancer of Zeste Homolog 2 in Patients with Resected Small Cell Lung Cancer.
Toyokawa G; Takada K; Tagawa T; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Takamori S; Akamine T; Hirai F; Yamada Y; Hamamoto R; Oda Y; Maehara Y
Anticancer Res; 2018 Jun; 38(6):3707-3711. PubMed ID: 29848731
[TBL] [Abstract][Full Text] [Related]
37. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression.
ten Heuvel SE; Hoekstra HJ; Bastiaannet E; Suurmeijer AJ
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):189-95. PubMed ID: 18997619
[TBL] [Abstract][Full Text] [Related]
38. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients.
Ladanyi M; Antonescu CR; Leung DH; Woodruff JM; Kawai A; Healey JH; Brennan MF; Bridge JA; Neff JR; Barr FG; Goldsmith JD; Brooks JS; Goldblum JR; Ali SZ; Shipley J; Cooper CS; Fisher C; Skytting B; Larsson O
Cancer Res; 2002 Jan; 62(1):135-40. PubMed ID: 11782370
[TBL] [Abstract][Full Text] [Related]
39. EZH2 overexpression in head and neck cancer is related to lymph node metastasis.
Nienstedt JC; Schroeder C; Clauditz T; Simon R; Sauter G; Muenscher A; Blessmann M; Hanken H; Pflug C
J Oral Pathol Med; 2018 Mar; 47(3):240-245. PubMed ID: 29285811
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
